psychiatryПСИХИАТРИЯPsychiatry (Moscow) (Psikhiatriya)1683-83192618-6667FSBSI “The Mental Health Research Centre”; LLC «Publisher «MIA»2618-6667-2018-77-86-96psychiatry-319Research ArticleНАУЧНЫЕ ОБЗОРЫSCIENTIFIC REVIEWSНегативные симптомы шизофрении: современные зарубежные концепции и патофизиологические механизмы. Ч. 1Negative symptoms of schizophrenia: the conceptualization and pathophysiological mechanisms. Part 1ПавличенкоАлексей ВикторовичPavlichenkoAlexey

кандидат медицинских наук, доцент, кафедра психиатрии, наркологиии психотерапии

PgD, MD, assistant professor

apavlichenko76@gmail.comМосковский государственный медико-стоматологический университет им. А.И. Евдокимова, МоскваРоссияA.I. Jevdokimov Moscow State University of Medicine and Dentistry, MoscowRussian Federation2018311020181778696Copyright © Павличенко А.В., 20182018Павличенко А.В.Pavlichenko A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.journalpsychiatry.com/jour/article/view/319

Данный обзор подготовлен по материалам 25-го конгресса Европейской психиатрической ассоциации (апрель 2017 г., Флоренция) участником проекта «Восточноевропейская академия Всемирной психиатрической ассоциации и компании «Сервье» специально для психиатрических журналов Зоны 10 ВПА (East European Educational WPA — Servier Academy — «EEE WPA-Servier Academy»). Концепция негативных расстройств претерпела существенные изменения в последние годы. Одними из значимых достижений в данной области стала дифференциация негативных расстройств на первичные (связанные с болезненным процессом) и вторичные (связанные с другими причинами, такими как позитивные симптомы, депрессия, побочные эффекты препаратов), а также выделение двух кластеров симптомов: абулии (включая отсутствие мотивации, ангедонию и снижение социальной активности) и снижения экспрессии (включая притупление аффекта и бедность речи), которые могут оказывать различное влияние на функциональные исходы болезни.

The conceptualization of negative symptoms has evolved in recent years; it is largely recognized that negative symptoms may be primary (related to the disease process) or secondary to other factors (i.e. positive symptoms, depression, side effects of drug treatment) and cluster in two dimensions: avolition (including amotivation, anhedonia and asociality) and defcit of expression (including affective flattening and alogia) that might have a different impact on functional outcome.

шизофрениядомены негативных расстройствпервичные и вторичные негативные симптомыschizophreniadomains of negative symptomsprimary and secondary negative symptomspathophysiologyReferencesCrow T.J. Positive and negative schizophrenia symptoms and the role of dopamine. The British Journal of Psychiatry. 1981;139(3):251– 254. doi: 10.1192/bjp.139.3.251Crow T.J. Positive and negative schizophrenia symptoms and the role of dopamine. The British Journal of Psychiatry. 1981;139(3):251– 254. doi: 10.1192/bjp.139.3.251Mäkinen J., Miettunen J., Isohanni M., Koponen H. Negative symptoms in schizophrenia: A review. Nordic Journal of Psychiatry. 2008;62(5):334–341. doi: 10.1080/08039480801959307Mäkinen J., Miettunen J., Isohanni, M., Koponen, H. Negative symptoms in schizophrenia: A review. Nordic Journal of Psychiatry. 2008;62(5):334–341. doi :10.1080/08039480801959307Pogue-Geile M.F., Zubin J. Negative symptomatology and schizophrenia: A conceptual and empirical review. International Journal of Mental Health. 1987;16(4):3–45. doi: 10.1080/00207411.1987.11449074Pogue-Geile M.F., & Zubin J. Negative symptomatology and schizophrenia: A conceptual and empirical review. International Journal of Mental Health. 1987;16(4):3–45. doi: 10.1080/00207411.1 987.11449074Galderisi S., Mucci A., Bitter I., Libiger J., Bucci P., Fleischhacker W., for the EUFEST Study Group. Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial. European Neuropsychopharmacology. 2013;23(3):196–204. doi: 10.1016/j.euroneuro.2012.04.019Galderisi S., Mucci A., Bitter I., Libiger J., Bucci P., Fleischhacker W., for the EUFEST Study Group. Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial. European Neuropsychopharmacology. 2013;23(3):196–204. doi: 10.1016/j.euroneuro.2012.04.019Chen L., Johnston J.A., Kinon B.J., Stauffer V., Succop, P., Marques T.R., Ascher-Svanum H. The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial. BMC Psychiatry. 2013;13(1). doi: 10.1186/1471-244x- 13-320Chen L., Johnston J.A., Kinon B.J., Stauffer V., Succop P., Marques T.R., Ascher-Svanum H. The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial. BMC Psychiatry. 2013;13(1). doi: 10.1186/1471-244x- 13-320Cornblatt B., Obuchowski M. The hillside study of risk and early detection in schizophrenia: Early findings. Schizophrenia Research. 1998;29(1–2):10. doi: 10.1016/s0920-9964(97)88309-0Cornblatt B., Obuchowski M. The hillside study of risk and early detection in schizophrenia: Early findings. Schizophrenia Research. 1998;29(1–2):10. doi: 10.1016/s0920-9964(97)88309-0Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS Consensus Statement on Negative Symptoms. Schizophrenia Bulletin. 2006;32(2):214–219. doi: 10.1093/schbul/ sbj053Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS Consensus Statement on Negative Symptoms. Schizophrenia Bulletin. 2006;32(2):214–219. doi: 10.1093/schbul/ sbj053Carpenter Jr.W.T., Heinrichs D.W., Wagman A.M. Deficit and nondeficit forms of schizophrenia: the concept. American Journal of Psychiatry. 1988;145(5):578–583. doi: 10.1176/ajp.145.5.578Carpenter Jr.W.T., Heinrichs D.W., Wagman A.M. Deficit and nondeficit forms of schizophrenia: the concept. American Journal of Psychiatry. 1988;145(5):578–583. doi: 10.1176/ajp.145.5.578Galderisi S., Färden A., Kaiser S. Dissecting negative symptoms of schizophrenia: History, assessment, pathophysiological mechanisms and treatment. Schizophrenia Research. 2017;186:1–2. doi: 10.1016/j.schres.2016.04.046Galderisi S., Färden A., Kaiser S. Dissecting negative symptoms of schizophrenia: History, assessment, pathophysiological mechanisms and treatment. Schizophrenia Research. 2017;186:1–2. doi: 10.1016/j.schres.2016.04.046Buchanan R.W. Persistent negative symptoms in schizophrenia: An overview. Schizophrenia Bulletin. 2007;33(4):1013–1022. doi: 10.1093/ schbul/sbl057Buchanan R.W. Persistent negative symptoms in schizophrenia: An overview. Schizophrenia Bulletin. 2007;33(4):1013–1022. doi: 10.1093/ schbul/sbl057Galderisi S., Bucci P., Mucci A., Kirkpatrick B., Pini S., Rossi A., Maj M. Categorical and dimensional approaches to negative symptoms of schizophrenia: Focus on long-term stability and functional outcome. Schizophrenia Research. 2013;147(1):157–162. doi: 10.1016/j. schres.2013.03.020Galderisi S., Bucci P., Mucci A., Kirkpatrick B., Pini S., Rossi A., Maj M. Categorical and dimensional approaches to negative symptoms of schizophrenia: Focus on long-term stability and functional outcome. Schizophrenia Research. 2013;147(1):157–162. doi: 10.1016/j. schres.2013.03.020Couture S.M., Granholm E.L., Fish S.C. A path model investigation of neurocognition, theory of mind, social competence, negative symptoms and real-world functioning in schizophrenia. Schizophrenia Research. 2011;125(2–3):152–160. doi: 10.1016/j. schres.2010.09.020Couture S.M., Granholm E.L., Fish S.C. A path model investigation of neurocognition, theory of mind, social competence, negative symptoms and real-world functioning in schizophrenia. Schizophrenia Research. 2011;125(2–3):152–160. doi: 10.1016/j. schres.2010.09.020Galderisi S., Rossi A., Rocca P., Bertolino A., Mucci A., Bucci P. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry. 2014;13(3):275–287. doi: 10.1002/ wps.20167Galderisi S., Rossi A., Rocca P., Bertolino A., Mucci A., Bucci P. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry. 2014;13(3):275–287. doi: 10.1002/ wps.20167Strassnig M.T., Raykov T., O’Gorman C., Bowie C.R., Sabbag S., Durand D., Harvey P.D. Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity. Schizophrenia Research. 2015; 165(1):76–82. doi: 10.1016/j.schres.2015.03.033Strassnig M.T., Raykov T., O’Gorman C., Bowie C.R., Sabbag S., Durand D., Harvey P.D. Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity. Schizophrenia Research. 2015; 165(1):76–82. doi: 10.1016/j.schres.2015.03.033Stahl S.M., Buckley P.F. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr. Scand. 2007; Jan;115(1):4–11.Stahl S.M., Buckley P.F. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr. Scand. 2007; Jan;115(1):4–11.Kirkpatrick B., Strauss G.P., Nguyen L., Fischer B.A., Daniel D.G., Cienfuegos A., Marder S.R. The Brief Negative Symptom Scale: Psychometric properties. Schizophrenia Bulletin. 2010;37(2):300–305. doi: 10.1093/schbul/sbq059Kirkpatrick B., Strauss G.P., Nguyen L., Fischer B.A., Daniel D.G., Cienfuegos A., Marder S.R. The Brief Negative Symptom Scale: Psychometric properties. Schizophrenia Bulletin. 2010;37(2):300–305. doi: 10.1093/schbul/sbq059Kring A.M., Gur R.E., Blanchard J.J., Horan W.P., Reise S.P. The Clinical Assessment Interview for Negative Symptoms (CAINS): Final development and validation. American Journal of Psychiatry. 2013;170(2):165–172. doi: 10.1176/appi.ajp.2012.12010109Kring A.M., Gur R.E., Blanchard J.J., Horan W.P., Reise S.P. The Clinical Assessment Interview for Negative Symptoms (CAINS): Final development and validation. American Journal of Psychiatry. 2013;170(2):165–172. doi: 10.1176/appi.ajp.2012.12010109Lyne J., Renwick L., O’Donoghue B., Kinsella A., Malone K., Turner N., Clarke M. Negative symptom domain prevalence across diagnostic boundaries: The relevance of diagnostic shifts. Psychiatry Research. 2015;228(3):347–354. doi: 10.1016/j.psychres.2015.05.086Lyne J., Renwick L., O’Donoghue B., Kinsella A., Malone K., Turner N., Clarke M. Negative symptom domain prevalence across diagnostic boundaries: The relevance of diagnostic shifts. Psychiatry Research. 2015;228(3):347–354. doi: 10.1016/j.psychres.2015.05.086Kirkpatrick B. Developing concepts in negative symptoms. The Journal of Clinical Psychiatry. 2014;75(suppl. 1):3–7. doi: 10.4088/ jcp.13049su1c.01Kirkpatrick B. Developing concepts in negative symptoms. The Journal of Clinical Psychiatry. 2014;75(suppl. 1):3–7. doi: 10.4088/ jcp.13049su1c.01Chen L., Johnston J.A., Kinon B.J., Stauffer V., Succop P., Marques T.R., Ascher-Svanum H. The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial. BMC Psychiatry. 2013;13(1). doi: 10.1186/1471-244x- 13-320Chen L., Johnston J.A., Kinon B.J., Stauffer V., Succop P., Marques T.R., Ascher-Svanum H. The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial. BMC Psychiatry. 2013;13(1). doi: 10.1186/1471-244x- 13-320Kelley M.E., van Kammen D.P., Allen D.N. Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am. J. Psychiatry. 1999;156:406–411.Kelley M.E., van Kammen D.P., Allen D.N. Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am. J. Psychiatry. 1999;156:406–411.Tandon R., DeQuardo J.R. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr. Res. 2000;45:191–201.Tandon R., DeQuardo J.R. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr. Res. 2000;45:191–201.Siris S.G., Addington D., Azorin, J.-M., Falloon I.R., Gerlach J., Hirsch S.R. Depression in schizophrenia: recognition and management in the USA. Schizophrenia Research. 2001;47(2–3):185–197. doi: 10.1016/s0920-9964(00)00135-3Siris S.G., Addington D., Azorin J.-M., Falloon I. R., Gerlach J., Hirsch S.R. Depression in schizophrenia: recognition and management in the USA. Schizophrenia Research. 2001;47(2–3):185–197. doi: 10.1016/s0920-9964(00)00135-3Kuck J., Zisook S. Negative symptomatology in schizophrenic outpatients. The Journal of Nervous and Mental Disease. 1992;180(8):510–515. doi: 10.1097/00005053-199208000-00006Kuck J., Zisook S. Negative symptomatology in schizophrenic outpatients. The Journal of Nervous and Mental Disease. 1992;180(8):510–515. doi: 10.1097/00005053-199208000-00006Lanсon C. Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS). Journal of Affective Disorders. 2000; 58(2):107–115. doi: 10.1016/s0165-0327(99)00075-0Lanсon C. Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS). Journal of Affective Disorders. 2000; 58(2):107–115. doi: 10.1016/s0165-0327(99)00075-0Siris S.G. Depression in schizophrenia: perspective in the era of «atypical» antipsychotic agents. Am. J. Psychiatry. 2000;157:1379– 1389.Siris S.G. Depression in schizophrenia: perspective in the era of «atypical» antipsychotic agents. Am. J. Psychiatry. 2000;157:1379– 1389.Lako I.M., Bruggeman R. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia. J. Affect. Disord. 2012;140:38–47. doi: 10.1016/j.jad.2011.10.014Lako I.M., Bruggeman R. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia. J. Affect. Disord. 2012;140:38–47. doi: 10.1016/j.jad.2011.10.014Leucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry. 2008;14(4):429–447. doi: 10.1038/sj.mp.4002136Leucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry. 2008;14(4):429–447. doi: 10.1038/sj.mp.4002136Hasan A., Falkai P., Wobrock T., Lieberman J., Glenthøj B., Gattaz W.F. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, suicidality, substance use disorders and pregnancy and lactation. The World Journal of Biological Psychiatry. 2015;16(3):142–170. doi: 10.3109/15622975.2015.1009163Hasan A., Falkai P., Wobrock T., Lieberman J., Glenthøj B., Gattaz W.F. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, suicidality, substance use disorders and pregnancy and lactation. The World Journal of Biological Psychiatry. 2015;16(3):142–170. doi: 10.3109/15622975.2015.1009163Pani L., Gessa G.L. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Molecular Psychiatry. 2002;7(3):247–253. doi: 10.1038/sj.mp.4001040Pani L., Gessa G.L. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Molecular Psychiatry. 2002;7(3):247–253. doi: 10.1038/sj.mp.4001040Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B. A., Keller W. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophrenia Bulletin. 2009;36(1):71–93. doi: 10.1093/schbul/sbp116Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer, B. A., Keller W. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophrenia Bulletin. 2009;36(1):71–93. doi: 10.1093/schbul/sbp116Park C.-H., Park T.-W., Yang J.C., Lee K.-H., Huang G.-B., Tong Z., Chung Y.-C. No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol. International Clinical Psychopharmacology. 2012;27(2):114–120. doi: 10.1097/yic.0b013e3283502773Park C.-H., Park T.-W., Yang J.C., Lee K.-H., Huang G.-B., Tong Z., Chung Y.-C. No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol. International Clinical Psychopharmacology. 2012;27(2):114–120. doi: 10.1097/yic.0b013e3283502773Fusar-Poli P., Papanastasiou E., Stahl D., Rocchetti M., Carpenter W., Shergill S., McGuire P. Treatments of negative symptoms in schizophrenia: Meta-analysis of 168 randomized placebocontrolled trials. Schizophrenia Bulletin. 2014;41(4):892–899. doi: 10.1093/schbul/sbu170Fusar-Poli P., Papanastasiou E., Stahl D., Rocchetti M., Carpenter W., Shergill S., McGuire P. Treatments of negative symptoms in schizophrenia: Meta-analysis of 168 randomized placebo-controlled trials. Schizophrenia Bulletin. 2014;41(4):892–899. doi: 10.1093/schbul/sbu170Peralta V., Cuesta M.J., Martinez-Larrea A., Serrano J.F. Differentiating primary from secondary negative symptoms in schizophrenia: A study of neuroleptic-naive patients before and after treatment. American Journal of Psychiatry. 2000;157(9):1461–1466. doi: 10.1176/appi.ajp.157.9.1461Peralta V., Cuesta M.J., Martinez-Larrea A., Serrano J.F. Differentiating primary from secondary negative symptoms in schizophrenia: A study of neuroleptic-naive patients before and after treatment. American Journal of Psychiatry. 2000;157(9):1461–1466. doi: 10.1176/ appi.ajp.157.9.1461Kirschner M., Aleman A., Kaiser S. Secondary negative symptoms: A review of mechanisms, assessment and treatment. Schizophrenia Research. 2017;186:29–38. doi: 10.1016/j.schres.2016.05.003Kirschner M., Aleman A., Kaiser S. Secondary negative symptoms: A review of mechanisms, assessment and treatment. Schizophrenia Research. 2017;186:29–38. doi: 10.1016/j.schres.2016.05.003Fervaha G., Takeuchi H., Lee J., Foussias G., Fletcher P.J., Agid O., Remington G. Antipsychotics and amotivation. Neuropsychopharmacology. 2015;40(6):1539–1548. doi: 10.1038/npp.2015.3Fervaha G., Takeuchi H., Lee J., Foussias G., Fletcher P. J., Agid O., Remington G. Antipsychotics and amotivation. Neuropsychopharmacology. 2015;40(6):1539–1548. doi: 10.1038/npp.2015.3Takeuchi H., Suzuki T. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr. Bull. 2013;39:993–998.Takeuchi H., Suzuki T. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr. Bull. 2013;39:993–998.Oshima I., Mino Y. Effects of environmental deprivation on negative symptoms of schizophrenia: a nationwide survey in Japan’s psychiatric hospitals. Psychiatry Res. 2005;136:163–171. doi. org/10.1016/j.psychres.2005.06.001Oshima I., Mino Y. Effects of environmental deprivation on negative symptoms of schizophrenia: a nationwide survey in Japan’s psychiatric hospitals. Psychiatry Res. 2005;136:163–171. doi. org/10.1016/j.psychres.2005.06.001Nordentoft M., Welcher B., Knudsen H.C., Krasnik A., Jessen-Petersen B., Treufeldt P. CCPP-Copenhagen Community Psychiatric Project. Social Psychiatry and Psychiatric Epidemiology. 1996;31(6):336–344. doi: 10.1007/bf00783422Nordentoft M., Welcher B., Knudsen H.C., Krasnik A., Jessen-Petersen B., Treufeldt P. CCPP-Copenhagen Community Psychiatric Project. Social Psychiatry and Psychiatric Epidemiology. 1996;31(6):336–344. doi: 10.1007/bf00783422Elis O., Caponigro J.M., Kring A.M. Psychosocial treatments for negative symptoms in schizophrenia: Current practices and future directions. Clinical Psychology Review. 2013;33(8):914–928. doi: 10.1016/j.cpr.2013.07.001Elis O., Caponigro J.M., Kring, A.M. Psychosocial treatments for negative symptoms in schizophrenia: Current practices and future directions. Clinical Psychology Review. 2013;33(8):914–928. doi: 10.1016/j.cpr.2013.07.001Rovai L., Maremmani A.G. Negative dimension in psychiatry. Amotivational syndrome as a paradigm of negative symptoms in substance abuse. Riv. Psichiatr. 2013;48:1–9. doi: 10.1708/1228.13610Rovai L., Maremmani A.G. Negative dimension in psychiatry. Amotivational syndrome as a paradigm of negative symptoms in substance abuse. Riv. Psichiatr. 2013;48:1–9. doi: 10.1708/1228.13610Garfield J.B.B., Lubman D.I., Yücel M. Anhedonia in substance use disorders: A systematic review of its nature, course and clinical correlates. Australian & New Zealand Journal of Psychiatry. 2013;48(1):36–51. doi: 10.1177/0004867413508455.Garfield J.B.B., Lubman D.I., Yücel M. Anhedonia in substance use disorders: A systematic review of its nature, course and clinical correlates. Australian & New Zealand Journal of Psychiatry. 2013;48(1):36–51. doi: 10.1177/0004867413508455.

The authors declare that there are no conflicts of interest present.